Solventum Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $8.3B+0.7% YoYTTM through 30 Jun 2026
Net Income $1.4B+199.4% YoYTTM through 30 Jun 2026
Free Cash Flow -$118MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 53.5% |
| EBITDA Margin | 31.1% |
| Operating Margin | 26.2% |
| Net Margin | 17.3% |
Returns
30.8%ROE
10.9%ROA
16.0%ROIC
Balance Sheet Health
Debt / Equity1.00x
Current Ratio1.23x
Net Debt$4.2B
Cash & Equivalents$403M
Quality Metrics
Altman Z-Score2.22
Piotroski F-Score4 / 9
FCF Margin-1.4%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $8.3B
Diluted EPS$8.18TTMFY2025: $8.88
Dividend
No dividend
Capital Allocation
R&D Spend$725M
Capex Intensity3.9%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| MedSurg | $4.8B | +3.9% | |
| Dental Solutions | $1.3B | ||
| Health Information Systems | $1.4B |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.